Allied Market Research

2024

Postmenopausal Vaginal Atrophy Drugs Market

Postmenopausal Vaginal Atrophy Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report by Therapy Type and by Drug Form : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy. Symptoms of vaginal atrophy include redness, burning, itching, dyspareuia, and irritation. Diagnosis for PVA includes pelvic examination, vaginal smear test, vaginal activity test, blood test, and urine test.

Presence of favorable healthcare reforms, high unmet medical needs across emerging economies, and gradual shift from systemic estrogen treatments, such as vaginal gels, and patches, to non-estrogenic therapies drive the market. In addition, rise in prevalence of postmenopausal vaginal atrophy further accelerates the market growth. However, low diagnosis rate, and risk associated with the existing treatment options restricts the market. The advent of novel drugs with improved safety are expected to tap the unmet needs and provide lucrative market growth opportunities.

The report segments the global PVA market based on therapy type and drug forms. Based on therapy type, the market is categorized into estrogen-based drugs (Premarin, Vagifem, Estrace, Estring and Femring) and non-estrogen-based drugs (BZA/CE, Osphena, and Vaginorm). Based on drug forms, the market is categorized as vaginal gels, creams, tablets, rings, and patches. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global PVA market include Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., Shionogi & Company, Limited, Allergan plc, and Shionogi & Co. Ltd.

Key Benefits

  • The study provides an in-depth analysis of the global PVA market and the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market¬†to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on product assists to understand the trends in the industry.
  • Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

Postmenopausal Vaginal Atrophy Drugs Market Report Highlights

Aspects Details
icon_5
By Therapy Type
  • Estrogen Based Drugs
  • Premarin
  • Vagifem
  • Estrace
  • Estring
  • Femring
  • Non Estrogen Based Drugs
  • BZA or CE
  • Osphena
  • Vaginorm
icon_6
By Drug Form
  • Vaginal Gels
  • Creams
  • Tablets
  • Rings
  • Patches
icon_7
By Region
  • North America 
  • Europe 
  • Asia-Pacific 
  • LAMEA 
icon_8
Key Market Players

Novo Nordisk AS, Allergan plc, Pfizer Inc., Bionovo, Inc., Shionogi and Company, Limited, Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., Endoceutics, Inc., Actavis plc, Shionogi and Co. Ltd

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Postmenopausal Vaginal Atrophy Drugs Market

Global Opportunity Analysis and Industry Forecast, 2023-2032